Eledon Pharmaceuticals discusses updated long-term results from its Phase 2 BESTOW clinical trial in kidney transplantation, according to two Seeking Alpha items that reference an investor communication transcript and an accompanying slideshow. The updates focus on longer-term follow-up in the trial population and provide additional context on how the therapy is performing over time. The reports indicate that the company is presenting the newest available efficacy and safety information associated with the Phase 2 study in kidney transplant recipients. As presented in the transcript and slideshow materials, the company reviews the status of the program and highlights findings from extended monitoring rather than only initial or short-term outcomes. The Seeking Alpha summaries do not provide specific numerical results or full methodological detail in the text provided here, but they emphasize that the purpose of the update is to inform investors about the trial’s longer-term trajectory. Overall, the coverage centers on the company’s communication of updated long-term Phase 2 data related to its kidney transplantation indication, as part of ongoing clinical development.